Biotech Forum
The 8th Congress of the French Neuroscience Society will provide a unique opportunity to scientists, clinical researchers and decision-makers of the biotechnology world to meet and to exchange views on subjects of common interest in the field of neuroscience research. Space has been provided to biotechnology companies to present their activities and know-how to researchers. A round table is organized on themes such a how to create a company, how to increase its value, and on the subject of public-private relationships.
For further information, please contact us.
Addex applies state of the art technologies in biology and chemistry for drug development programs with the objective of reducing time to market and attrition rates. Furthermore, Addex has developed a specific know-how for the development of compounds which modulate allosterically specific CNS targets, in particular G-protein coupled receptors.
www.addexpharma.com
Advicenne Pharma is a biopharmaceutical company focused on the research and development of drugs targeting orphan or emergent diseases in particular, for treating or diagnosing Central Nervous System (CNS) Disorders. Advicenne Pharma is developing a portfolio of original molecules and markers for diagnosis and treatment of CNS Orphan diseases including neurodegenerative disorders, neurodevelopmental disorders, feeding behaviours dysfunctions, neuropathic pain and inflammatory diseases.
www.advicenne.com
ANS Biotech mission is to perform in vivo studies for pain management in order to evaluate new active drugs provided by pharmaceutical and biotech companies, using clinically relevant animal models
www.ans-biotech.com
BIOalternatives provides in vitro services and preclinical research (high content screening and mechanistic assays) for pharmaceutical companies in the fields of neurobiology, skin pathology, inflammation & immunomodulation... BIOalternatives neurobiology department offers numerous in vitro assays related to central neuronal degenerative diseases, peripheral neuropathies, neuroprotection against hypoxia (ischemia and stroke), demyelinating diseases, pain, neurogenesis and develop specific customers models.
www.bioalternatives.com
Biocortech is a biopharmaceutical company committed to the discovery and development of new pharmaceutical compounds active on the Central Nervous System to treat neuropsychiatric disorders (depression, schizophrenia, cognitive deficits) via the restoration of deficient receptors and pathways in the brain.
http://www.biocortech.com
Bracer BioTech designs and integrates automatic microfluidic devices dedicated to biologic applications. We propose you the DynXcellsTM line to pilot biologic fluids and to control in vitro cells environment during experimentation or cells culture. Our goal is to give you a perfect control of experiments conditions, piloting physical and chimical parameters (Temperature, pH, media composition, fluids flow...). That's way, using DynXcellsTM, you dramatically improve reproductibility and make such fluidic device easy to use.
CELLIAL Technologies is specialized in the studies of transport of molecules through the blood-brain barrier. CELLIAL Technologies is a spin-off from an academic research group from the Pasteur Institute of Lille, based on 11 years of academic research and screening of molecules on an in vitro blood-brain barrier for pharmaceutical companies.
www.cellial.com
The mission of the CENA is dedicated to characterise the effects of synthetics molecules (promnesiant medicament) or naturals (nutraceutics) on the mnesic decline due to the ageing on aged or pathologic animals models (Schizophrenia, mice tg Alzheimer, …), for that, we use three complementary approaches, a “behavioural approach”, “a brain imaging approach” and “a cellular approach” (electrophysiological protocols and with the study of the mitochondrial metabolism).
http://www.cena.u-bordeaux1.fr
Cisbio international in vitro technologies is an established developer of technologies that are used in assay development and drug screening procedures to enhance drug discovery. The company is also a pioneer in the field of homogenous fluorescence methodologies via its proprietary technology, HTRF®, and produces a selection of biological reagents and methods used for the investigation of biomolecular interactions.
www.htrf.com
Eurogentec was founded in 1985 as a spin-off from the University of Liège (Belgium). Our mission is to design and deliver reliable and innovative services and products for the Life-Science community. As a leading supplier in genomic and proteomic research, Eurogentec is able to offer its customers integrated solutions, whether they use DNA, antibodies, peptides or proteins as research tools. Eurogentec also offers research and development services for the biopharmaceutical industry. We can be your partner from the research bench through to production.
www.eurogentec.com
Euroscreen is a biotechnology company applying its G protein-coupled receptors (GPCRs) expertise to deorphanization, internal drug discovery programs, research collaborations, services and custom screenings.
Our core expertise lays in high-throughput functional screening of GPCRs for deorphanization, drug discovery, pharmacological profiling and characterization of small molecules and functional antibodies.
www.euroscreen.be
FaustPharmaceuticals SA is a biopharmaceutical company focusing on CNS disorders. Faust is developing products for early "Proof of Concept" clinical studies (up to phase IIb). Its most advanced compound, FP0011, is in phase II for ALS, Parkinson's and Migraine.
www.faustpharma.com
Genepep est une société spécialisée dans la découverte, la synthèse et l'optimisation de nouveaux peptides thérapeutiques (nouveaux ligands peptidiques et nouveaux peptides lytiques)
www.genepep.com
Funded to meet the needs of scientists in the field of genomic, Genoscreen offers an easy access to the best (state-of-the-art) molecular tools and technologies through a broad range of services of recognized quality. Thanks to its expertise, Genoscreen is currently implicated in innovating research projects to identify new therapeutical targets in Alzheimer’s Disease, to develop molecular pharmacogenetic tools for cardiovascular and metabolic diseases.
www.genoscreen.fr
Greenpharma is a French CRO established in Orleans since 2000 and specialized in research of new bioactive compounds for biopharmaceutical companies. Natural drugs, Drug repositioning, Drug associations and Drug mimetism are four approaches proposed in the GreenOvation concept which includes analytical, medicinal and computational chemistries. This strategy allows to obtain leads with a strong potential in term of development facilities and time to market.
www.greenpharma.com
Helios Biosciences selects and classifies therapeutic targets and biomarkers of diseases with complex determinism. The company proposes to its customers solutions of dynamic system biology (proprietary technology) which start from the construction of the networks of molecular interactions implied in a physiopathological phenomenon and finish by the construction of predictive dynamic models of the evolution of these networks (allowing an accurate selection of therapeutic targets) while passing by the determination of the pathways followed by the signal within the network.
Helios proposes also the characterization of gene expression on tissue sections.
http://www.heliosbiosciences.com
Key-Obs is a preclinical contract research company specialized in CNS. Key-Obs conducts in vivo research in various fields: Screening, Telemetry, Memory, Learning, Aging, Alzheimer disease, Depression, Anxiety, Psychosis, Drug abuse, Pharmacodependence, Vigilance, Attention, Impulsivity, Parkinson and Huntington diseases. Key-Obs has developed specific targeted tests: pharmacodependence, neuroprotective drugs, antidepressants, behavioral phenotyping of transgenic animals, ADHD (attention deficit hyperactivity disorder).
www.key-obs.com
Neuréva is dedicated to the development of new therapeutic strategies to treat traumatic and degenerative CNS diseases. A wide range of in vitro and in vivo models as well as innovative analytical tools enable us to screen the safety and efficacy of new therapeutic products. In addition to its drug discovery programme, Neuréva also provides services to the pharmaceutical industry and offers its integrated platform and know-how.
www.neureva.com
NeuroService is a French CRO company that proposes standardized in vitro safety and pharmacological tests based on acute brain slices recording with Multi-Electrode Array (MEA). The company is developing its own robotic platform.
www.neuroservice.fr
Mitochondria are involved in aged related neuronal diseases such as Alzheimer and Parkinson. Oxincell provides mitochondrial synergic analysis for drug discovery and safety evaluation, useful in neurodegenerative field.
www.oxincell.com
Pharmaxon is a science-based biopharmaceutical company specializing in the discovery and development of innovative therapies that control cell mobility. This cutting-edge approach opens the way to therapeutic solutions for a number of diseases, lesions and cancers with huge medical needs, with an initial focus on the central and peripheral nervous systems. Ongoing R&D programs include acute spinal cord injury, glioblastoma, and mild cognitive impairment.
www.pharmaxon.com
Porsolt & Partners Pharmacology is an independent Contract Research Organization. As a niche CRO, we specialize in animal pharmacology and we have been providing tailored and high quality solutions for over twenty years. We cover most of the areas of central nervous system pharmacology, including pain and, cardiovascular, respiratory, gastro-intestinal, and renal/urogenital pharmacology; more recent developments are in the area of metabolism & eating disorders. We perform both efficacy and safety studies. We are awarded a Grade A GLP compliance certificate from the French government.
www.porsolt.com
Skuld-Tech is an innovative biotechnology company dedicated to genomics. Its mission is to select and validate biomarkers leading to design new diagnosis, identify new targets, generate new leads for biopharmaceutical companies and tailor treatments.
www.skuldtech.com
The mission of SynapCell is to bring a high added-value to CNS drug development in developing smart solutions for preclinical evaluation of CNS therapeutics and providing consulting, pre-designed and customized programs to expertise drug candidates of the biopharmaceutical industry.
www.synapcell.com
TheraGenetics is a spin out company based on pharmacogenetic research from the Institute of Psychiatry, King's College London. TheraGenetics' focus is personalised medicine, developing and commercialising a portfolio of pharmacogenetic response and side effect prediction tests to guide and improve the treatment of CNS disorders; matching the medication to the patient.
www.TheraGenetics.com/
Theraptosis is a biopharmaceutical company that designs and develops various drugs that act on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases.
www.theraptosis.com
Trophos is a biopharmaceutical company developing drugs to prevent neuronal loss in patients with neurodegenerative disease.
www.trophos.com
